BioSpace News Archive

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced select preliminary financial results for the third quarter ended August 31, 2020. For the third quarter of fiscal year 2020, the company expects consolidated net revenues to be between $13.8 million and $14.2 million compared to $16.1 million for the third quarter

Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF)(DE: MMQ), the leading drug development company for psychedelic inspired medicines, is evaluating an expanded United States investor base through an up-listing on the NASDAQ Capital Market (“NASDAQ

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of clinical-stage assets designed to modulate immunological pathways that are implicated across a spectrum of diseases, today announced that the company will host a virtual Rilonacept Analyst Day on Monday, September 28th, 2020

A fungal infection is also known as mycosis. It is a skin disease caused by a fungus. There are a million species of fungi.

EASD, the leading European association in the field of diabetes, has selected the positive results of the international Phase II clinical study on TOTUM-63 in prediabetes to be presented next September in its 56th annual meeting. These results were selected by the American Diabetes Association last June 2020.

Universal Diagnostics, an in-vitro diagnostics company developing minimally-invasive, blood-based solutions for detecting cancer early, announced that promising new data for its investigational advanced adenoma detection blood test and multi-cancer detection test was presented at the European Society for Medical Oncology Virtual Congress 2020.

Inflazome is a pioneering inflammasome company developing orally available NLRP3 inflammasome inhibitors to address clinical unmet needs across a wide variety of inflammatory diseases

Fennec Pharmaceuticals Inc. announced that the U.S. Patent and Trademark Office will issue U.S. Patent 10,792,363 entitled “Anhydrous Sodium Thiosulfate and Formulations Thereof.”

Updated guidelines represent a significant milestone in the adoption of Itamar’s Peripheral Arterial Tonometry (PAT) based Home Sleep Apnea Testing (HSAT) in Europe, following adoption in the UK, Holland, and Sweden

ASLAN Pharmaceuticals, a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced that clinical sites in the US and Australia are now open and ready to enrol patients into its multiple ascending dose study testing the first-in-class therapeutic antibody ASLAN004 in moderate to severe atopic dermatitis patients.